Schizophrenia - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Schizophrenia Emerging Therapy and TPP Insights

Thelansis's "Schizophrenia Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Schizophrenia Overview

Schizophrenia is a chronic, disabling psychiatric disorder characterized by positive symptoms (hallucinations, delusions, disorganized speech) and negative symptoms (social withdrawal, avolition, blunted affect). Its multifactorial etiology involves genetic vulnerability, environmental stressors, and dysregulation of dopamine, glutamate, and acetylcholine pathways. Diagnosis relies on clinical psychiatric assessment using DSM-5-TR or ICD-11 criteria, both of which emphasize dimensional symptom severity rather than historical, rigid clinical subtypes. Management requires lifelong, multidisciplinary care combining psychosocial interventions with advanced pharmacotherapy. While traditional antipsychotics rely on dopamine D2 receptor antagonism, the modern therapeutic paradigm preferentially deploys next-generation oral muscarinic receptor agonists (such as xanomeline-trospium) to effectively modulate circuits and alleviate symptoms without causing extrapyramidal or metabolic side effects, utilizing acute hospitalization to ensure safety during severe exacerbations.

Key Highlights

• In the United States, diagnosis rates are high, with ~95% of cases identified, reflecting strong clinical awareness and screening.
• Approximately 77% of patients receive drug treatment (2025), indicating a notable gap between diagnosis and treatment uptake.
• Persistent unmet need exists in managing negative and cognitive symptoms, which significantly impact long-term functioning.
• Treatment adherence remains a critical challenge, driving relapse rates and repeated hospitalizations.
• Increasing adoption of long-acting injectable antipsychotics (LAIs) to improve compliance and reduce disease burden.

Market Overview

• The Italy schizophrenia market is projected to grow from $304M to $335M, reflecting modest market expansion.
• Market growth is driven by:
• Increased uptake of long-acting injectable therapies
• Expansion of maintenance treatment strategies
• Despite stable patient population growth, market value is supported by chronic treatment duration and relapse prevention strategies.
• Continued innovation in novel antipsychotics and digital/behavioral interventions is expected to shape future market dynamics.
• Future growth will depend on therapies addressing negative symptoms, cognitive deficits, and adherence improvement.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• LB Pharmaceuticals Inc.
• Vanda Pharmaceuticals
• Novartis Pharmaceuticals
• AbbVie
• Eli Lilly and Company
• Otsuka Pharmaceutical Co., Ltd.
• Anavex Life Sciences Corp.
• Anxo Pharmaceutical Co., Ltd.
• Qilu Pharmaceutical Co., Ltd.
• Spinogenix
• MapLight Therapeutics
• Bristol-Myers Squibb
• Boryung Pharmaceutical Co., Ltd
• Click Therapeutics, Inc.
• Merck Sharp & Dohme LLC
• Hoffmann-La Roche
• Celon Pharma SA
• Boehringer Ingelheim
• ACADIA Pharmaceuticals Inc.
• Janssen-Cilag Ltd.
• Intra-Cellular Therapies, Inc.
• NeuShen Therapeutics
• Newron Pharmaceuticals SPA
• Alto Neuroscience
• Alkermes, Inc.